Skip to main content

17.11.2014
Raphael Scharfmann

U1016 INSERM-Institut, Cochin Groupe Hospitalier Cochin-Port-Royal, Paris, France

“Beta Cell Development: From Rodent to Human”

 

03.11.2014
Óscar Fernández-Capetillo

Spanish National Cancer Research Center, Madrid, Spain

“Targeting oncogene-induced DNA damage for cancer therapy”

 

06.10.2014
Lucas Pelkmans

Institute of Molecular Life Sciences, University of Zurich, Switzerland

“Cell-intrinsic adaptation of lipid composition to local crowding drives social behavior”

 

14.07.2014
Kathryn Moore

Departments of Medicine and Cell Biology, NYU Langone Medical Center and School of Medicine, New York, United States

“Mechanisms of chronic inflammation in metabolic diseases”


23.06.2014
Benjamin Cravatt

Department of Chemical Physiology, The Skaggs Institute for Chemical Biology

The Scripps Research Institute, La Jolla, CA, United States

“Activity-based proteomics – applications for enzyme and inhibitor discovery”


31.03.2014
Christopher Glass

Cellular & Molecular Medicine, University of California San Diego, La Jolla, CA, United States

“A genome wide view of macrophage activation”

 

24.03.2014
Holger Sondermann

Department of Molecular Medicine, Cornell University, Ithaca, NY, United States

“The Ins and Outs of c-di-GMP Signaling in Bacterial Biofilm Formation”

 

17.02.2014
Thomas Helleday

Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden

“Targeting MTH1 for de-personlised anti-cancer treatment”

 

10.02.2014
Janet Kelso

The Minerva Research Group for Bioinformatics, Max Planck Institute for Evolutionary Anthropology, Leipzig, Germany

“What we have learned from sequencing ancient genomes”

 

20.01.2014
Thirumala-Devi Kanneganti

Department of Immunology, St. Jude Children’s Research Hospital, Memphis, TN, United States

“Regulators of Inflammatory Responses”

 

13.01.2014
Olli Kallioniemi

Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Finland

“Individually optimized cancer therapies for Acute Myeloid Leukemia and beyond”